A new payment policy proposal released by the Centers for Medicare and Medicaid Services (CMS) this week covers digital tools used for behavioural health, which could be a boost for the dig
A Connecticut federal judge has sided with the US Department of Health and Human Services (HHS) in Boehringer Ingelheim's challenge to Medicare’s drug price negotiation programme, rejecting
The House Ways and Means Committee in the US voted in favour of a new bill which would end a two-decade-long restriction on the coverage of drugs to treat obesity under Medicare.
Lawmakers across the political divide have accused the pharma industry of abusing the patent system to keep the prices of their products as high as possible in a combative
A report issued by the office of US Senator Bernie Sanders has claimed that the high prices being charged for new GLP-1 agonist-based obesity therapies like Novo Nordisk’s
In another setback for the pharma industry, a US federal judge has rejected a bid to overturn the Medicare pricing negotiation brought by Bristol-Myers Squibb and Johnson